Gilead Sciences, Inc.
GILD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $137,973,000 | $138,033,150 | $139,614,300 | $115,277,760 |
| - Cash | $9,354,000 | $5,144,000 | $7,926,000 | $9,991,000 |
| + Debt | $2,806,000 | $24,946,000 | $24,952,000 | $27,322,000 |
| Enterprise Value | $131,425,000 | $157,835,150 | $156,640,300 | $132,608,760 |
| Revenue | $7,769,000 | $7,081,000 | $6,667,000 | $7,569,000 |
| % Growth | 9.7% | 6.2% | -11.9% | – |
| Gross Profit | $6,200,000 | $5,580,000 | $5,127,000 | $5,988,000 |
| % Margin | 79.8% | 78.8% | 76.9% | 79.1% |
| EBITDA | $4,583,000 | $3,374,000 | $2,605,000 | $3,109,000 |
| % Margin | 59% | 47.6% | 39.1% | 41.1% |
| Net Income | $3,052,000 | $1,960,000 | $1,315,000 | $1,783,000 |
| % Margin | 39.3% | 27.7% | 19.7% | 23.6% |
| EPS Diluted | 2.43 | 1.56 | 1.04 | 1.42 |
| % Growth | 55.8% | 50% | -26.8% | – |
| Operating Cash Flow | $4,108,000 | $827,000 | $1,757,000 | $2,975,000 |
| Capital Expenditures | -$147,000 | -$107,000 | -$104,000 | -$147,000 |
| Free Cash Flow | $3,961,000 | $720,000 | $1,653,000 | $2,828,000 |